Opakalim clinical trials
Also written BHV-7000.
How each study uses opakalim is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the opakalim studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
9 studies that test it; most in 2024 (8)
| Year | Studies |
|---|---|
| 2024 | 8 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 9 · Other 0
Biohaven Therapeutics Ltd. (9)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 3, 1 in phase 3
Studies that test opakalim, phase 3 first.
- Dec 2026A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset EpilepsyPhase 2/3 · Biohaven Therapeutics Ltd.
- Dec 2026Long-term Safety and Tolerability of BHV-7000Phase 2 · Biohaven Therapeutics Ltd.
- Nov 2027A Phase 1b Study of BHV-7000 in Participants With Inherited ErythromelalgiaPhase 1 · Biohaven Therapeutics Ltd.
Studies
Open first, then newest update. How each study uses opakalim is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 9
- Long-term Safety and Tolerability of BHV-7000Enrolling by invitationPhase 2Biohaven Therapeutics Ltd.NCT06443463Written as BHV-7000
- A Phase 1b Study of BHV-7000 in Participants With Inherited ErythromelalgiaActive, not recruitingPhase 1Biohaven Therapeutics Ltd.NCT07262268Written as BHV-7000
- Long-term Safety Study of BHV-7000 in Participants With Major Depressive Disorder (MDD)CompletedPhase 2Biohaven Therapeutics Ltd.NCT06423781Written as BHV-7000
- Efficacy and Safety Study of BHV-7000 Monotherapy in Major DepressionCompletedPhase 2Biohaven Therapeutics Ltd.NCT06419608Written as BHV-7000
- A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset EpilepsyActive, not recruitingPhase 2/3Biohaven Therapeutics Ltd.NCT06132893Written as BHV-7000
- Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset EpilepsyActive, not recruitingPhase 2/3Biohaven Therapeutics Ltd.NCT06309966Written as BHV-7000
- A Study to Determine if BHV-7000 is Effective and Safe in Adults With Idiopathic Generalized Epilepsy With Generalized Tonic-clonic SeizuresTerminatedPhase 2/3Biohaven Therapeutics Ltd.NCT06425159Written as BHV-7000
- BHV-7000 Acute Treatment of Bipolar ManiaCompletedPhase 2/3Biohaven Therapeutics Ltd.NCT06419582Written as BHV-7000
- BHV-7000 Open-Label Extension Bipolar Mania StudyTerminatedPhase 2Biohaven Therapeutics Ltd.NCT06423794Written as BHV-7000
Codes
What other systems call opakalim · ClinicalTrials.gg INT015390
- UNII (FDA) 73H9J7RBA2OPAKALIMOne source FDA
- NCI Thesaurus C215751OpakalimOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 73H9J7RBA2 | OPAKALIM | One source FDA |
| NCI Thesaurus | C215751 | Opakalim | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.